Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of pazopanib versus pazopanib plus gemcitabine in relapsed or metastatic soft tissue sarcoma
2009-017261-32Phase 2Completed
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in soft tissue sarcoma (STS) comparing Pazopanib monotherapy with Pazopanib plus gemcitabine (2 arms). Primary endpoint: Progression-free survival rate at 12 weeks. Started May 2011; status: completed.
02
Drugs
pazopanibgemcitabine
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2009-017261-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017261-32.